3-氯-丙烷-1-磺酸甲基酰胺 | 83635-06-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 中文名称: 3-氯-丙烷-1-磺酸甲基酰胺
• 英文名称: 3-chloro-propane-1-sulfonic acid methylamide
• 英文别名: N-methyl-3-chloropropane-1-sulfonamide；N-methyl-3-chloropropanesulfonamide；3-chloro-N-methylpropane-1-sulfonamide；N-methyl-3-chloropropylsulfonamide
• CAS: 83635-06-7
• 化学式: C₄H₁₀ClNO₂S
• mdl: MFCD12107241
• 分子量: 171.648
• InChiKey: HNFPTYFTHBATEF-UHFFFAOYSA-N

物化性质

• 沸点：
  261.0±42.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-氯-丙烷-1-磺酸甲基酰胺 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 苯 为溶剂， 反应 24.0h， 以75%的产率得到N-甲基-1,1-二氧代-异噻唑烷
  参考文献：
  名称：

  Novel Antiarthritic Agents with 1,2-Isothiazolidine-1,1-dioxide (γ-Sultam) Skeleton: Cytokine Suppressive Dual Inhibitors of Cyclooxygenase-2 and 5-Lipoxygenase

  摘要：

  Various 1,2-isotkiazolidine-1,1-dioxide (gamma-sultam) derivatives containing an antioxidant moiety, 2i6-di-tert-butylphenol substituent, were prepared. Some compounds, which have a lower alkyl group at the 2-position of the gamma-sultam skeleton, showed potent inhibitory effects on both cyclooxygenase (COX)-2 and 5-lipoxygenase (5-LO), as well as production of interleukin (IL)-1 in in vitro assays. They also proved to be effective in several animal arthritic models without any ulcerogenic activities. Among these compounds, (E)-(5)-(3,5-di-tert-butyl-4-hydroxybenzyliclene)-2-ethyl-1,2-isothiazolidine-1, (S-2474) was selected as an antiarthritic drug candidate and is now under clinical trials. The structure-activity relationships (SAR) examined and some pharmacological evaluations are described.

  DOI：

  10.1021/jm9906015
• 作为产物：
  描述：

  3-氯丙烷磺酰氯 、 盐酸甲胺 在 苄基三甲基氯化铵 、 potassium carbonate 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 生成 3-氯-丙烷-1-磺酸甲基酰胺
  参考文献：
  名称：

  Novel Antiarthritic Agents with 1,2-Isothiazolidine-1,1-dioxide (γ-Sultam) Skeleton: Cytokine Suppressive Dual Inhibitors of Cyclooxygenase-2 and 5-Lipoxygenase

  摘要：

  Various 1,2-isotkiazolidine-1,1-dioxide (gamma-sultam) derivatives containing an antioxidant moiety, 2i6-di-tert-butylphenol substituent, were prepared. Some compounds, which have a lower alkyl group at the 2-position of the gamma-sultam skeleton, showed potent inhibitory effects on both cyclooxygenase (COX)-2 and 5-lipoxygenase (5-LO), as well as production of interleukin (IL)-1 in in vitro assays. They also proved to be effective in several animal arthritic models without any ulcerogenic activities. Among these compounds, (E)-(5)-(3,5-di-tert-butyl-4-hydroxybenzyliclene)-2-ethyl-1,2-isothiazolidine-1, (S-2474) was selected as an antiarthritic drug candidate and is now under clinical trials. The structure-activity relationships (SAR) examined and some pharmacological evaluations are described.

  DOI：

  10.1021/jm9906015
• 作为试剂：
  描述：

  3-氯丙烷磺酰氯 、 盐酸甲胺 、 potassium carbonate 、 在 苄基三甲基氯化铵 Sodium sulfate-III 、 silica gel 、 3-氯-丙烷-1-磺酸甲基酰胺 作用下， 以 乙酸乙酯 为溶剂， 反应 2.0h， 以to give 12 g (74%) of crude N-methyl-3-chloropropylsulfonamide (intermediate 3b) as a pale yellow oil的产率得到3-氯-丙烷-1-磺酸甲基酰胺
  参考文献：
  名称：

  Benzylidene derivatives

  摘要：

  以下式I所示的苯甲醛衍生物具有抗炎活性：##STR1## 其中A是-CH.sub.2-或-CH.sub.2 CH.sub.2-；B是键或-CH.sub.2-，-CHOH-，-CO-，-O-，或A和B可以共同形成-CH=CH-；D是>N-或>CH-；R.sup.1和R.sup.2各自独立地是氢，低烷基或低烷氧基；R.sup.3是氢，低烷基，环烷基，低烷氧基，芳基烷氧基，杂芳基烷氧基，低烷基羰基，芳基羰基，取代或未取代的氨基甲酰基，或式-(CH.sub.2).sub.n-R.sup.4的基团，其中R.sup.4是氢，羟基，取代或未取代的氨基，芳基，杂芳基，羟基羰基或低烷氧羰基；n是0-3的整数。

  公开号：

  US05418230A1

文献信息

• [EN] NOVEL IMIDAZOLIDINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS IMIDAZOLIDINE
  申请人：CHUGAI PHARMACEUTICAL CO LTD

  公开号：WO2006013887A1

  公开（公告）日：2006-02-09

  Compounds represented by the general formula (I); and drugs and medicinal compositions, containing the compounds: (I) wherein n is an integer of 1 to 20; Q is (II) or (III) A is cyano or the like; B is hydrogen, halogeno, or the like; X1 and X2 are each independently selected from between O and S; E is C1-4 alkyl; and R1, R2, R3 and R4 are each independently selected from between hydrogen and C1-6 alkyl.

  通式（I）代表的化合物；以及含有这些化合物的药物和药用组合物：（I）中n是1到20的整数；Q是（II）或（III）A是氰基或类似物；B是氢、卤素或类似物；X1和X2分别独立地从O和S之间选择；E是C1-4烷基；R1、R2、R3和R4分别独立地从氢和C1-6烷基之间选择。
• [EN] MACROCYCLIC INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS DE L'INTÉGRASE MACROCYCLIQUE
  申请人：TIBOTEC PHARM LTD

  公开号：WO2011121105A1

  公开（公告）日：2011-10-06

  Compound having Formula (I) and pharmaceutically acceptable salts or solvates thereof, their pharmaceutical formulations and use as HIV inhibitors.

  具有化学式（I）的化合物及其药用盐或溶剂化合物，它们的药物配方以及作为HIV抑制剂的用途。
• Synthetic Studies on Condensed-Azole Derivatives. I. Synthesis and Anti-asthmatic Activities of .OMEGA.-Substituted Alkylthioimidazo(1,2-b)pyridazines.
  作者：Masaaki KUWAHARA、Yasuhiko KAWANO、Tatsuhiko KAWAI、Yasuko ASHIDA、Akio MIYAKE

  DOI：10.1248/cpb.43.1505

  日期：——

  A series of novel ω-substituted alkylthioimidazo[1, 2-b]pyridazines was designed and synthesized in an effort to find a novel anti-asthmatic agent. The anti-asthmatic activity of these compounds was evaluated ont he basis of their ability to inhibit thromboxane A2 synthetase and platelet activating factor (PAF)-induced bronchoconstriction in guinea pigs. None of these compounds significantly inhibited thromboxane A2 synthetase, though, sulfonamide derivatives potently inhibited PAF-induced bronchoconstriction. Among them, 3-(imidazo[1, 2-b]pyridazin-6-yl)thiopropanesulfonamide (5) showed the most potent inhibitory effect. The anti-asthmatic effects of compound 5 in experimental models were superior to those of theophylline.

  为了找到一种新型抗哮喘药物，我们设计并合成了一系列新型ω-取代烷基硫代咪唑并[1，2-b]哒嗪。根据这些化合物抑制血栓素 A2 合成酶和血小板活化因子（PAF）诱导的豚鼠支气管收缩的能力，对它们的抗哮喘活性进行了评估。这些化合物都不能明显抑制血栓素 A2 合成酶，但磺酰胺衍生物能有效抑制 PAF 诱导的支气管收缩。其中，3-(咪唑并[1, 2-b]哒嗪-6-基)硫代丙磺酰胺（5）的抑制作用最强。化合物 5 在实验模型中的抗哮喘效果优于茶碱。
• Antirheumatic agent
  申请人：——

  公开号：US20030125364A1

  公开（公告）日：2003-07-03

  A novel antirheumatic agent comprising as an active ingredient a compound of formula I: 1 or a pharmaceutically acceptable salt or hydrate thereof.

  一种新型的抗风湿药物，其活性成分为公式I:1的化合物或其药学上可接受的盐或水合物。
• Antirheumatic
  申请人：Shionogi & Co., Ltd.

  公开号：US06525081B1

  公开（公告）日：2003-02-25

  A novel antirheumatic agent comprising as an active ingredient a compound of formula I: or a pharmaceutically acceptable salt or hydrate thereof.

  一种新的抗风湿药物，其活性成分为公式I的化合物，或其药学上可接受的盐或水合物。